305 related articles for article (PubMed ID: 33576497)
1. Prevention of conjunctivitis in patients with atopic dermatitis undergoing treatment with dupilumab: an Italian single-centre experience.
Simonetti O; Radi G; Diotallevi F; Molinelli E; Rizzetto G; Offidani A
Clin Exp Dermatol; 2021 Jul; 46(5):939-940. PubMed ID: 33576497
[No Abstract] [Full Text] [Related]
2. Conjunctivitis in Dupilumab Clinical Trials for Adolescents with Atopic Dermatitis or Asthma.
Bansal A; Simpson EL; Paller AS; Siegfried EC; Blauvelt A; de Bruin-Weller M; Corren J; Sher L; Guttman-Yassky E; Chen Z; Daizadeh N; Kamal MA; Shumel B; Mina-Osorio P; Mannent L; Patel N; Graham NMH; Khokhar FA; Ardeleanu M
Am J Clin Dermatol; 2021 Jan; 22(1):101-115. PubMed ID: 33481203
[TBL] [Abstract][Full Text] [Related]
3. Dupilumab-Associated Conjunctivitis in Patients With Atopic Dermatitis: A Multicenter Real-Life Experience.
Nettis E; Bonzano L; Patella V; Detoraki A; Trerotoli P; Lombardo C;
J Investig Allergol Clin Immunol; 2020; 30(3):201-204. PubMed ID: 31932274
[No Abstract] [Full Text] [Related]
4. Dupilumab-Associated Conjunctivitis in Patients With Atopic Dermatitis.
Liberman P; Shifera AS; Berkenstock M
Cornea; 2020 Jun; 39(6):784-786. PubMed ID: 31985517
[TBL] [Abstract][Full Text] [Related]
5. [Ocular symptoms associated with dupilumab in atopic dermatitis].
Voorberg AN; Oosterhaven JAF; Wijdh RHJ; de Bruin-Weller MS; Schuttelaar MLA
Ned Tijdschr Geneeskd; 2019 Mar; 163():. PubMed ID: 30945835
[TBL] [Abstract][Full Text] [Related]
6. Real-world effectiveness and safety of dupilumab for the treatment of atopic dermatitis in Japanese patients: a single-centre retrospective study.
Uchida H; Kamata M; Mizukawa I; Watanabe A; Agematsu A; Nagata M; Fukaya S; Hayashi K; Fukuyasu A; Tanaka T; Ishikawa T; Ohnishi T; Tada Y
Br J Dermatol; 2019 Nov; 181(5):1083-1085. PubMed ID: 31127860
[No Abstract] [Full Text] [Related]
7. Treatment of moderate-to-severe atopic dermatitis with dupilumab in real clinical practice: a multicentre, retrospective case series.
Armario-Hita JC; Pereyra-Rodriguez J; Silvestre JF; Ruiz-Villaverde R; Valero A; Izu-Belloso R; Jáuregui-Presa I; Curto-Barredo L; Figueras-Nart I; Herranz-Pinto P; Herraez-Herrera L; Ortiz-de-Frutos FJ; Martinez-Pilar L; Sastre J; Serra-Baldrich E
Br J Dermatol; 2019 Nov; 181(5):1072-1074. PubMed ID: 31021399
[No Abstract] [Full Text] [Related]
8. Conjunctivitis in patients with atopic dermatitis treated with dupilumab is associated with higher baseline serum levels of immunoglobulin E and thymus and activation-regulated chemokine but not clinical severity in a real-world setting.
Uchida H; Kamata M; Nagata M; Fukaya S; Hayashi K; Fukuyasu A; Tanaka T; Ishikawa T; Ohnishi T; Tada Y
J Am Acad Dermatol; 2020 May; 82(5):1247-1249. PubMed ID: 31884090
[No Abstract] [Full Text] [Related]
9. Dupilumab and the risk of conjunctivitis and serious infection in patients with atopic dermatitis: A propensity score-matched cohort study.
Schneeweiss MC; Kim SC; Wyss R; Schneeweiss S; Merola JF
J Am Acad Dermatol; 2021 Feb; 84(2):300-311. PubMed ID: 33038471
[TBL] [Abstract][Full Text] [Related]
10. A Clinician's Guide to the Recognition and Management of Dupilumab-Associated Conjunctivitis.
Agnihotri G; Shi K; Lio PA
Drugs R D; 2019 Dec; 19(4):311-318. PubMed ID: 31728936
[TBL] [Abstract][Full Text] [Related]
11. Incidence of Conjunctivitis and Other Ocular Surface Disorders in Patients With Long-Term Dupilumab Use.
Jo CE; Georgakopoulos JR; Drucker AM; Piguet V; Yeung J
J Cutan Med Surg; 2020; 24(5):527-528. PubMed ID: 32449620
[No Abstract] [Full Text] [Related]
12. Effectiveness and Safety of Long-Term Dupilumab Treatment in Elderly Patients with Atopic Dermatitis: A Multicenter Real-Life Observational Study.
Patruno C; Fabbrocini G; Longo G; Argenziano G; Ferrucci SM; Stingeni L; Peris K; Ortoncelli M; Offidani A; Amoruso GF; Talamonti M; Girolomoni G; Grieco T; Iannone M; Nettis E; Foti C; Rongioletti F; Corazza M; Veneri MD; Napolitano M;
Am J Clin Dermatol; 2021 Jul; 22(4):581-586. PubMed ID: 33725337
[TBL] [Abstract][Full Text] [Related]
13. Treatment of refractory conjunctivitis associated to dupilumab with topical pimecrolimus applied to the eyelid skin.
Sernicola A; Gattazzo I; Di Staso F; Giordano D; Capalbo A; Persechino F; Scuderi G; Persechino S
Dermatol Ther; 2019 Nov; 32(6):e13134. PubMed ID: 31639238
[TBL] [Abstract][Full Text] [Related]
14. Conjunctivitis in atopic dermatitis patients with and without dupilumab therapy - international eczema council survey and opinion.
Thyssen JP; de Bruin-Weller MS; Paller AS; Leshem YA; Vestergaard C; Deleuran M; Drucker AM; Foelster-Holst R; Traidl-Hoffmann C; Eyerich K; Taieb A; Su JC; Bieber T; Cork MJ; Eichenfield LF; Guttman-Yassky E; Wollenberg A
J Eur Acad Dermatol Venereol; 2019 Jul; 33(7):1224-1231. PubMed ID: 31056788
[TBL] [Abstract][Full Text] [Related]
15. Management of dupilumab-associated conjunctivitis in atopic dermatitis.
Aszodi N; Thurau S; Seegräber M; de Bruin-Weller M; Wollenberg A
J Dtsch Dermatol Ges; 2019 May; 17(5):488-491. PubMed ID: 30873757
[TBL] [Abstract][Full Text] [Related]
16. Ocular adverse events in patients with atopic dermatitis undergoing treatment with dupilumab: An Italian single-center experience.
Napolitano M; Di Guida A; Fabbrocini G; Patruno C
Dermatol Ther; 2021 Sep; 34(5):e15059. PubMed ID: 34241938
[TBL] [Abstract][Full Text] [Related]
17. Cyclosporine 0.1% (Ikervis
Roca-Ginés J; Rahhal-Ortuño M; Torres-Navarro I; Rodríguez-Serna M; Navarro-Mira MÁ
Arch Soc Esp Oftalmol (Engl Ed); 2019 Aug; 94(8):396-399. PubMed ID: 31178231
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness and safety of dupilumab for atopic dermatitis in a liver transplant recipient: a case report.
Ludriksone L; Elsner P; Malessa C; Settmacher U; Schliemann S
J Dtsch Dermatol Ges; 2020 Jul; 18(7):740-742. PubMed ID: 32212242
[No Abstract] [Full Text] [Related]
19. Goblet cell scarcity and conjunctival inflammation during treatment with dupilumab in patients with atopic dermatitis.
Bakker DS; Ariens LFM; van Luijk C; van der Schaft J; Thijs JL; Schuttelaar MLA; van Wijk F; Knol EF; Balak DMW; van Dijk MR; de Bruin-Weller MS
Br J Dermatol; 2019 May; 180(5):1248-1249. PubMed ID: 30597515
[No Abstract] [Full Text] [Related]
20. Real-world evidence of dupilumab efficacy and risk of adverse events: A systematic review and meta-analysis.
Halling AS; Loft N; Silverberg JI; Guttman-Yassky E; Thyssen JP
J Am Acad Dermatol; 2021 Jan; 84(1):139-147. PubMed ID: 32822798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
